source
- ARPA-H earmarks $160 million for custom gene-editing therapies, sparking debate on adequacyARPA-H announced a $160 million investment to support development of bespoke gene‑editing treatments. This follows a recent case where an infant was rescued from a lethal disease using a personaliz…
- AstraZeneca and Ionis see pivotal trial miss for ATTR-CM drug WainuaAstraZeneca announced that its experimental therapy Wainua, developed with Ionis, failed to meet primary endpoints in a pivotal study for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). T…